Role of NPT2b in health and chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 4, 2014, Pages 377-384

  Sabbagh, Yves ^a   Schiavi, Susan C ^a  

^a SANOFI   (France)

Author keywords

Chronic kidney disease; Hyperphosphatemia; Intestine; Npt2b

Indexed keywords

CLAUDIN; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; NICOTINAMIDE; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHATE TRANSPORTER; SEVELAMER; SODIUM PHOSPHATE COTRANSPORTER 2B; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23;

CHRONIC KIDNEY DISEASE; DROSOPHILA; DRUG TARGETING; DUODENUM; EXPERIMENTAL MODEL; GENE MUTATION; HUMAN; HYPERPHOSPHATEMIA; ILEUM; IN VIVO STUDY; JEJUNUM; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; CHRONIC KIDNEY FAILURE; GENETICS; HOMEOSTASIS; INTESTINE; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; HYPERPHOSPHATEMIA; INTESTINES; PHOSPHATES; RECEPTOR CROSS-TALK; RENAL INSUFFICIENCY, CHRONIC; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE IIB;

EID: 84902280292     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000447015.44099.5f     Document Type: Review

References (69)

1. Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 2007; 69:341-359.
2. Alizadeh Naderi AS, Reilly RF. Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol 2010; 6:657-665.
3. Anderson JJB, Klemmer PJ, Watts MLS, et al. Phosphate. In: Bowman BA, Russel RM, editors. Knowledge in nutrition, 9th edn Washington DC: ILSI Press; 2006. pp. 383-395.
4. Berndt T, Knox FG. Renal regulation of phosphate excretion. In: Seldin DW, Giebisch G, editors. The kidney: physiology and pathology, 2nd edn New York: Raven Press; 1992. pp. 2511-2532.
5. Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74:148-157.
6. Hruska KA, Mathew S, Lund RJ, et al. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol 2009; 29:156-165.
7. Hruska KA, Saab G, Mathew S, Lund R. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 2007; 20:309-315.
8. Hruska KA, Slatopolsky E. Disorders of phosphorus, calcium, and magnesium metabolism. In: Schrier R, Gottschalk C, editors. Diseases of the kidney. London, England: Little, Brown and Company; 1996. pp. 2477-2526.
9. Sabbagh Y, Tenenhouse HS, EconsMJ. Mendelian hypophosphatemias. In: Beaudet AL, Vogelstein B, Kinzler KW, et al., editors. The online metabolic and molecular basis of inherited disease. New York, USA: McGraw-Hill; 2008. pp. 1-72.
10. Sabbagh Y, Giral H, Caldas Y, et al. Intestinal phosphate transport. Adv Chronic Kidney Dis 2011; 18:85-90.
11. Marks J, Srai SK, Biber J, et al. Intestinal phosphate absorption and the effect of vitamin D: a comparison of rats with mice. Exp Physiol 2006; 91:531-537.
12. Forster IC, Virkki L, Bossi E, et al. Electrogenic kinetics of a mammalian intestinal type IIb Na(+)/P(i) cotransporter. J Membr Biol 2006; 212:177-190.
13. Wagner CA, Hernando N, Forster IC, Biber J. The SLC34 family of sodiumdependent phosphate transporters. Pflugers Arch 2014; 466:139-153.
14. Ohi A, Hanabusa E, Ueda O, et al. Inorganic phosphate homeostasis in sodium-dependent phosphate co-Transporter Npt2b+/- mice. Am J Physiol Renal Physiol 2011; 301:F1105-F1113.
15. Schiavi SC, Tang W, Bracken C, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol 2012; 23:1691-1700.
16. Marks J, Debnam ES, Unwin RJ. Phosphate homeostasis and the renalgastrointestinal axis. Am J Physiol Renal Physiol 2010; 299:285-296.
17. Radanovic T, Wagner CA, Murer H, Biber J. Regulation of intestinal phosphate transport. I. Segmental expression and adaptation to low-P(i) diet of the type IIb Na(+)-P(i) cotransporter in mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2005; 288:G496-G500.
18. Kapus A, Szaszi K. Coupling between apical and paracellular transport processes. Biochem Cell Biol 2006; 84:870-880.
19. Amasheh S, Fromm M, Gunzel D. Claudins of intestine and nephron - A correlation of molecular tight junction structure and barrier function. Acta Physiol (Oxf) 2011; 201:133-140.
20. Giral H, Caldas Y, Sutherland E, et al. Regulation of rat intestinal Nadependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol 2009; 297:1466-1475.
21. Sabbagh Y, OBrien SP, Song W, et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 2009; 20:2348-2358.
22. Hilfiker H, Hattenhauer O, Traebert M, et al. Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci U S A 1998; 95:14564-14569.
23. Traebert M, Hattenhauer O, Murer H, et al. Expression of type II Na-P(i) cotransporter in alveolar type II cells. Am J Physiol 1999; 277:868-873.
24. Corut A, Senyigit A, Ugur SA, et al. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet 2006; 79:650-656.
25. Huqun, Izumi S, Miyazawa H, et al. Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med 2007; 175:263-268.
26. Olauson H, Brandenburg V, Larsson TE. Mutation analysis and serum FGF23 level in a patient with pulmonary alveolar microlithiasis. Endocrine 2010; 37:244-248.
27. Yin X, Wang H, Wu D, et al. SLC34A2 Gene mutation of pulmonary alveolar microlithiasis: report of four cases and review of literatures. Respir Med 2013; 107:217-222.
28. Ferreira Francisco FA, Pereira e Silva JL, Hochhegger B, et al. Pulmonary alveolar microlithiasis. State-of-The-Art review. Respir Med 2013; 107:1-9.
29. Hong SH, Minai-Tehrani A, Chang SH, et al. Knockdown of the sodiumdependent phosphate co-Transporter 2b (NPT2b) suppresses lung tumorigenesis. PLoS One 2013; 8:e7712.
30. Shibasaki Y, Etoh N, Hayasaka M, et al. Targeted deletion of the tybe IIb Na(+)-dependent Pi-co-Transporter, NaPi-IIb, results in early embryonic lethality. Biochem Biophys Res Commun 2009; 381:482-486.
31. Katai K, Tanaka H, Tatsumi S, et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999; 14:1195-1201.
32. Sabbagh Y. Phosphate as a sensor and signaling molecule. Clin Nephrol 2013; 79:57-65.
33. Mouillon JM, Persson BL. New aspects on phosphate sensing and signalling in Saccharomyces cerevisiae. FEMS Yeast Res 2006; 6:171-176.
34. Kido S, Miyamoto K, Mizobuchi H, et al. Identification of regulatory sequences and binding proteins in the type II sodium/phosphate cotransporter NPT2 gene responsive to dietary phosphate. J Biol Chem 1999; 274:28256-28263.
35. Bergwitz C, Rasmussen MD, DeRobertis C, et al. Roles of major facilitator superfamily transporters in phosphate response in Drosophila. PLoS One 2012; 7:e31730.
36. Bergwitz C, Wee MJ, Sinha S, et al. Genetic determinants of phosphate response in Drosophila. PLoS One 2013; 8:e56753.
37. Forster IC, Hernando N, Biber J, Murer H. Phosphate transporters of the SLC20 and SLC34 families. Mol Aspects Med 2013; 34:386-395.
38. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013; 75:503-533.
39. Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008; 199:271-277.
40. Lau WL, Pai A, Moe SM, Giachelli CM. Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis 2011; 18:105-112.
41. Sabbagh Y, Carpenter TO, Demay MB. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci U S A 2005; 102:9637-9642.
42. Barreto DV, Barreto Fde C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC study. Nephron Clin Pract 2008; 110:273-283.
43. Ferreira A, Frazao JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19:405-412.
44. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109:697-711.
45. Moe SM, Duan D, Doehle BP, et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003; 63:1003-1011.
46. Six I, Maizel J, Barreto FC, et al. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res 2012; 96:130-139.
47. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393-4408.
48. Maizel J, Six I, Dupont S, et al. Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure. Kidney Int 2013; 84:491-500.
49. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167:879-885.
50. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112-S119.
51. Ketteler M, Wolf M, Hahn K, Ritz E. Phosphate: a novel cardiovascular risk factor. Eur Heart J 2013; 34:1099-1101.
52. Martin KJ, Gonzalez EA. Prevention and control of phosphate retention/ hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Clin J Am Soc Nephrol 2011; 6:440-446.
53. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245-252.
54. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607-617.
55. Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112:2627-2633.
56. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
57. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
58. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
59. Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010; 55:773-799.
60. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113:S1-S130.
61. Lenglet A, Liabeuf S, Guffroy P, et al. Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R D 2013; 13:165-173.
62. Berndt TJ, Pfeifer JD, Knox FG, et al. Nicotinamide restores phosphaturic effect of PTH and calcitonin in phosphate deprivation. Am J Physiol 1982; 242:447-452.
63. Kempson SA, Colon-Otero G, Ou SY, et al. Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest 1981; 67:1347-1360.
64. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005; 20:1378-1384.
65. Rottembourg JB, Launay-Vacher V, Massard J. Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int 2005; 68:2911-2912.
66. Wakasugi H, Futami T, Muso E, et al. Thrombocytopenia and anemia induced by niceritrol used for amelioration of hyperphosphatemia in a hemodialysis patient. Nephron Clin Pract 2000; 86:97-98.
67. Caldas YA, Giral H, Cortazar MA, et al. Liver X receptor-Activating ligands modulate renal and intestinal sodium-phosphate transporters. Kidney Int 2011; 80:535-544.
68. Charmot D. Nonsystemic drugs: a critical review. Curr Pharm Des 2012; 18:1434-1445.
69. Navre M, Labonte ED, Carreras C, et al. Novel nonsystemic NaP2b inhibitors block intestinal phosphate uptake. Proceedings of ASN meeting 2011. J Am Soc Nephrol Abstract Supplement 2011; 22: TH-OR020.